E
Epic bio
Relentless focus on ushering in a new era of gene regulation
About Epic bio
Epic Bio is a pioneering startup operating in the field of genetic medicine, with a focus on developing innovative therapies to control gene expression and treat complex diseases. The company leverages the power of epigenetics, a system present in all mammalian cells that controls gene expression, to create new therapeutic possibilities.
The company's primary offering is its Gene Expression Modulation System (GEMS), a platform that allows for the creation of customized therapies for specific disease indications. This "mix and match" platform uses a toolbox of epigenomic modulators, providing vast possibilities for disease treatment.
Epic Bio operates in the biotechnology market, serving clients in the healthcare sector, including hospitals, clinics, and other medical institutions. The company's business model revolves around the development and sale of its GEMS platform and the therapies it can create. Revenue is generated through the sale of these therapies to healthcare providers and institutions.
The company also prides itself on being a place where individuals can advance their careers, do groundbreaking work, and make a real impact on the world. This is evidenced by their recognition in the 2023 Endpoints 20 Under 40 and the 2022 Endpoints Women in R&D.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2018
- Headquarters
- South San Francisco, United States
- Employees
- 44
- Open positions
- 7
- Dealroom signal
- 82.2/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Genetics and genomics, Epigenetics, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Mar 2025 | $68M | $272M | SOLVE FSHD · Ally Bridge Group | ↗ |
| GRANTOther financing | Apr 2023 | $0 | — | SOLVE FSHD | ↗ |
Growth signals
Latest recorded traffic for Epic bio is 5.6K monthly website visits, up 115.4% over the last three months. Epic bio's team declined 2.2% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
SOLVE FSHD
Series A1 investor entered at this stage
Ally Bridge Group
Other known investors1 additional known investor
Stanford University
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Epic bio on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Epic bio’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.